

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability/ issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:	
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	13/06/2018	11/01/2019	03/01/2019	18/01/2019	24/01/2019	15/02/2019	08/03/2019		56				Y								Delayed with sponsor. HRA not granted until 03/01/19. Realistic new FPFV target in the UK was 25/02/19. SIV at our site 30/01/19 and first patient recruited 08/03/19	Sponsor
17/LO/1847	216867	MUK twelve: A randomised phase II trial of Selinexor, cyclophosphamide and prednisolone vs cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients	23/07/2018	15/02/2019	04/01/2018	24/01/2019	22/02/2019	05/04/2019	13/05/2019		87							Y					Two participants were in screening, however first participant only recruited 13/05/2019	NHS Provider
18/EE/0272	242948	CamPROBE: Developing a safer and simple device for local anaesthetic transperineal prostate biopsies	06/12/2018	04/02/2019	10/01/2019	06/03/2019	08/03/2019	12/04/2019					Y										Recruitment Suspended by Sponsor just after opening to recruitment. Sponsor sought MHRA approval for adding new sites, all new sites were suspended to recruitment	Sponsor

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability/ issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
19/NW/0045	255691	I8B-MC-ITSB; A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-Peds	14/02/2019	10/04/2019	10/04/2019	24/04/2019	20/05/2019	03/06/2019	12/06/2019		63												
18/LO/0324	220073	The VIDEO Trial: A Feasibility Randomised Control Trial of Vitrectomy Plus Standard Care Intravitreal Ranibizumab Injections versus Standard Care Intravitreal Ranibizumab injections Alone In Patients With Centre Involving Diabetic Macular Edema	24/01/2019	22/05/2019	03/04/2018	01/07/2019	01/07/2019	10/07/2019	27/09/2019		128							Y				Five participants were in screening, however first two participants were only recruited 27/09/2019	NHS Provider

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability/ issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:	
18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/- intervention on outcomes in patients with non ST-elevation myocardial infarction	15/03/2019	25/06/2019	12/09/2018	02/08/2019	02/08/2019	08/08/2019	16/08/2019		52													
19/LO/0452	250324	CASTLE: Randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention in treatment naive children with rolandic epilepsy	27/03/2019	08/08/2019	02/05/2019	10/09/2019	17/09/2019	04/10/2019										Y				Four participants screened & approached, however participants have rejected the study. Site continuing to screen and approach potential participants (x2)	NHS Provider	

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability/ issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:	
18/YH/0358	242342	Sunflower: A randomised controlled trial to establish the clinical and cost effectiveness of expectant management versus pre-operative imaging with Magnetic Resonance Cholangiopancreatography (MRCP) in patients with symptomatic gallstones undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones	15/08/2018	28/05/2019	12/12/2018	28/05/2019	22/08/2019	23/08/2019	04/09/2019		99					Y							Delays to SIV due to lack of staff availability from NHS Provider	NHS Provider
19/LO/0236 (a)	230338	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	08/01/2020		119				Y								Sponsor delays, HRA approval for our site to be added (This record is for St Richard's Hospital Principal Investigator site)	Sponsor
19/LO/0236 (b)	230338	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	22/01/2020		119				Y								Sponsor delays, HRA approval for our site to be added (This record is for Worthing Hospital Principal Investigator site)	Sponsor

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability/issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:	
19/NE/0215	234453	Myeloma XIV (FITNESS). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	28/06/2019	02/12/2019	07/11/2019																			
																							The Sponsor is not ready to open sites; they hope to open sites in February 2020	Sponsor